Mydecine Innovations Group Inc.
MYCO
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -51.20K | 175.80K | 258.70K | 449.90K | 360.10K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -80.40K | 175.80K | 258.70K | -1.45M | 1.20M |
| Operating Income | 80.40K | -175.80K | -258.70K | 1.45M | -1.20M |
| Income Before Tax | 53.60K | -9.40K | -208.20K | 1.80M | -1.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 53.60K | -9.40K | -208.20K | 1.80M | -1.46M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 53.60K | -9.40K | -208.20K | 1.80M | -1.46M |
| EBIT | 80.40K | -175.80K | -258.70K | 1.45M | -1.20M |
| EBITDA | -- | -- | -- | 1.45M | -1.20M |
| EPS Basic | 0.04 | -0.01 | -0.17 | 1.46 | -1.18 |
| Normalized Basic EPS | 0.03 | -0.05 | -0.17 | 0.56 | -0.74 |
| EPS Diluted | 0.04 | -0.01 | -0.17 | 1.46 | -1.18 |
| Normalized Diluted EPS | 0.03 | -0.05 | -0.17 | 0.56 | -0.74 |
| Average Basic Shares Outstanding | 1.24M | 1.24M | 1.24M | 1.23M | 1.24M |
| Average Diluted Shares Outstanding | 1.24M | 1.24M | 1.24M | 1.23M | 1.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |